Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium

Tuesday, September 25, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

TOKYO, Sept. 25, 2018 /PRNewswire/ -- Anaeropharma Science Inc. headquartered in Tokyo (hereafter

"Anaeropharma") announced on September 25 that Anaeropharma and Astellas Pharma Inc. headquartered in Tokyo (hereafter "Astellas") have concluded a collaborative research agreement concerning
the creation of novel anti-tumor drugs that utilizes characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, in situ Delivery and Production System ("i-DPS"). An overview of the contract follows.

(Logo: https://kyodonewsprwire.jp/img/201809198120-O1-E6qt0Z44)

1. A collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes i-DPS technology

Under the terms of the agreement, the two companies shall conduct joint research regarding specific substances in order to create drug candidates for cancer therapy that utilizes Bifidobacterium as a drug delivery carrier. Astellas shall acquire the right of first negotiation regarding the exclusive licensing necessary for commercialization based on the results of this joint research. The agreement shall not constrain any research and development activities of i-DPS conducted by Anaeropharma applying to any molecules other than the above-mentioned specific substances.

2. About i-DPS and its Development Programs

Bifidobacterium is obligatory anaerobe which exists as enteroflora in the human body, and known as nonpathogenic bacteria. Solid cancers have immature vascular constructs and their interstitial tumors are in the state of hypoxia. The company aims to leverage the recombinant Bifidobacterium technology named i-DPS to create a new class of anti-cancer drugs. The technology offers broad potential to be more effective to solid tumors and generates anti-tumor drugs with less risks of adverse events than conventional anti-cancer drugs.

The leading development product using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S.

3. About Anaeropharma Science, Inc.

A privately held biopharmaceutical company based in Chiyoda-ku, Tokyo, Japan. Anaeropharma Science was established to pioneer the development of novel therapeutics to target a hypoxic environment in solid cancers based on its proprietary platform technology, i-DPS, using recombinant Bifidobacterium. The company's laboratory is located in the campus of Shinshu University in Matsumoto, Nagano Prefecture. Its CEO is Tetsuya Mishima.

Official website: http://www.anaeropharma.co.jp/

Cision View original content:http://www.prnewswire.com/news-releases/anaeropharma-science-signs-collaborative-research-agreement-with-astellas-on-creation-of-novel-anti-tumor-drugs-using-bifidobacterium-300718119.html

SOURCE Anaeropharma Science, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store